Celgene and Acceleron announced that the Food and Drug Administration (FDA) has granted Fast Track designations to luspatercept for use in two separate indications: for the treatment of patients with transfusion dependent beta-thalassemia and for the treatment of patients with non-transfusion dependent beta-thalassemia.

RELATED: Jadenu Tablets Approved for Chronic Iron Overload

Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members of the Transforming Growth Factor-beta (TGF-beta) superfamily involved in the late stages of erythropoiesis. It regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation, distinct from erythropoietin (EPO) which stimulates the proliferation of early-stage erythrocyte precursor cells.

For more information visit Celgene.com or Acceleron.com.